Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Allergy Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Allergy Other
    FDA Approves Ecallantide for Treatment of Acute Attacks of Hereditary Angio-Oedema in Patients 16 Years and Older - (DGNews)
    Inhaled Ciclesonide Improves Asthma Control: Presented at ACAAI - (DGDispatch)
    Efficacy of Aqueous Triamcinolone Acetonide in Allergic Rhinitis Not Affected by Gender: Presented at ACAAI - (DGDispatch)
    FDA Approves a C1-Esterase Inhibitor for Abdominal Attacks, Facial Swelling Associated With HAE - (DGNews)
    FDA Approves Bepotastine Besilate Solution for Ocular Itching Associated With Allergies - (DGNews)

    News archive

     Recent webcasts/CME - Allergy Other
    • Alpha1-Antitrypsin Deficiency: Incidence, Screening, and Management
    • Early Detection of Alpha1-Antitrypsin (AAT) Deficiency Helps Prevent Disease Progression
    • What Is the Best Approach to Treating Alpha1-Antitrypsin (AAT) Deficiency?
    • Advances in Hereditary Angioedema Treatment: Considerations, Criteria & the New Therapy Options for Treatment & Prevention of HAE Attacks
      Update in Hereditary Angioedema: A Disease in Rapid Evolution

      Webcasts/CME archive

       Recent cases - Allergy Other
        Gallbladder Edema in Type 1 Diabetic Patient due to Delayed-type Insulin Allergy
        Anaphylaxis Following Intravenous Fluorescein Angiography in a Vitreoretinal Clinic: Report of 4 Cases
        Acute Allergic Reaction due to Milk Proteins Contaminating Lactose Added to Corticosteroid for Injection
        Acute Generalized Exanthematous Pustulosis (AGEP) Triggered by a Spider Bite
        Anaphylactic Reaction to Camomile Tea

        Cases archive
          




        my personal edition > allergy other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Real-World Use of Fexofenadine Parallels Clinical Trials: Presented at EAACI

        By Jill Stein

        PARIS, FRANCE -- June 13, 2003 -- Treating allergic-rhinitis with fexofenadine in the real-world clinical setting delivers results that are in line with those reported in clinical trials, researchers announced here June 10th at the 22nd Congress of the European Academy of Allergology and Clinical Immunology.

        Claus Bachert, MD, PhD, from University Hospital of Ghent in Ghent, Belgium, presented findings from a post-marketing surveillance trial of fexofenadine that reviewed the clinical records of 13,007 patients with seasonal allergic rhinitis who were treated with the peripheral antihistamine fexofenadine.

        Overall, 5% of the cohort had mild disease, 54% had moderate disease, and 36% had severe disease. Information about disease severity was not available in 5% of patients. The researchers assessed symptoms of nasal obstruction, eye complaints, nose itching, rhinorrhoea and sneezing.

        Median time since the first occurrence of seasonal allergic rhinitis was 5 years, and mean treatment duration was 22 days.

        Fexofenadine treatment was associated with a marked decrease in severity of all five symptoms (P</=0.001). The total symptom score for all five symptoms was reduced from 2.20 to 0.51 category classes on a 5-point scale where scores ranged from 0 to 4. A score of zero refers to a complete absence of symptoms, 1 refers to mild symptoms, 2 means that symptoms are distinct, 3 denotes severe symptoms, and 4 indicates that symptoms are very severe.

        For 72.5% of patients, improvement was evident within 15 to 60 minutes after taking fexofenadine. Efficacy was rated as "very good" in 53% of cases, "good" in 38.09%, "satisfactory" in 3.81%, "sufficient" in 0.78%, and "insufficient" in 1.83% of cases.

        Side effects of fexofenadine included fatigue in 0.15% of patients, headache in 0.07%, and nausea in 0.07%. Serious adverse events were observed in three patients, one of whom had skin swelling.

        "The findings of this post-authorization survey in patients with seasonal allergic rhinitis demonstrate the good efficacy, tolerability, and safety of fexofenadine, and are in accordance with the results of clinical trials," Dr. Bachert said.

        This trial was sponsored by Aventis Pharma, in Bad Soden, Germany.


        [Study title: Fexofenadine In Clinical Practice: An Observation in 13000 Patients With Allergic Rhinitis. Abstract 984]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send